Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity

• Published in: Current oncology (Toronto) Vol. 29; no. 4; pp. 2530 - 2538
• Main Authors: Wells, J Connor, Fundytus, Adam, Sharma, Shubham, Hopman, Wilma M, Del Paggio, Joseph C, Gyawali, Bishal, Mukherji, Deborah, Hammad, Nazik, Pramesh, C S, Aggarwal, Ajay, Sullivan, Richard, Booth, Christopher M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 07-04-2022; MDPI AG
• Subjects: breast; Breast Neoplasms - therapy; cancer; design; Female; gastrointestinal; Humans; Lung; Lung Neoplasms - drug therapy; Medical Oncology; randomized controlled trial; Randomized Controlled Trials as Topic; gastrointestinal; lung; outcomes; design; cancer; breast; randomized controlled trial
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol29040207

Background: In this study, we compared and contrasted design characteristics, results, and publications of randomized controlled trials (RCTs) in gastrointestinal (GI), lung, and breast cancer. Methods: A PUBMED search identified phase III RCTs of anticancer therapy in GI, lung, and breast cancer published globally during the period 2014−2017. Descriptive statistics, chi-square tests, and the Kruskal−Wallis test were used to compare RCT design, results, and output across the cancer sites. Results: A total of 352 RCTs were conducted on GI (36%), lung (29%), and breast (35%) cancer. Surrogate endpoints were used in 55% of trials; this was most common in breast trials (72%) compared to GI (47%) and lung trials (43%, p < 0.001). Breast trials more often met their primary endpoint (54%) than GI (41%) and lung trials (41%) (p = 0.024). When graded with the ESMO-MCBS, lung cancer trials (50%, 15/30) were more likely to meet the threshold for substantial benefit. GI trials were published in journals with a substantially lower impact factor (IF; median IF 13) than lung (median IF 21) and breast cancer trials (median IF 21) (p = 0.038). Conclusions: Important differences in RCT design and output exist between the three major cancer sites. Use of surrogate endpoints and the magnitude of benefit associated with new treatments vary substantially across cancer sites.